Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

Chest
Jeffrey J PopmaJeffrey I Weitz

Abstract

This chapter about antithrombotic therapy during percutaneous coronary intervention (PCI) is part of the seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence Based Guidelines. Grade 1 recommendations are strong and indicate that the benefits do, or do not, outweigh risks, burden, and costs. Grade 2 suggests that individual patients' values may lead to different choices (for a full understanding of the grading, see Guyatt et al, CHEST 2004;126:179S-187S). Among the key recommendations in this chapter are the following: For patients undergoing PCI, we recommend pretreatment with aspirin, 75 to 325 mg (Grade 1A). For long-term treatment after PCI, we recommend aspirin, 75 to 162 mg/d (Grade 1A). For long-term treatment after PCI in patients who receive antithrombotic agents such as clopidogrel or warfarin, we recommend lower-dose aspirin, 75 to 100 mg/d (Grade 1C+). For patients who undergo stent placement, we recommend the combination of aspirin and a thienopyridine derivative (ticlopidine or clopidogrel) over systemic anticoagulation therapy (Grade 1A). We recommend clopidogrel over ticlopidine (Grade 1A). For all patients undergoing PCI, particularly those undergoing primary PCI, or those with refractory...Continue Reading

References

Apr 1, 1992·Journal of the American College of Cardiology·A M LincoffE J Topol
Jun 1, 1992·Journal of the American College of Cardiology·R K MylerB Hidalgo
Oct 1, 1991·The American Journal of Cardiology·R R TaylorP Luke
Mar 1, 1990·Journal of the American College of Cardiology·M L KnudtsonH J Duff
Jul 31, 1987·The American Journal of Cardiology·W D BussmannC Vallbracht
Nov 1, 1994·Journal of the American College of Cardiology·H Z FriedmanW W O'Neill
Apr 1, 1994·Journal of the American College of Cardiology·J J FergusonD R Leachman
Dec 31, 1997·Journal of the American College of Cardiology·J B MuhlesteinJ L Anderson
May 23, 1998·The New England Journal of Medicine·UNKNOWN Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS)
Sep 2, 1998·The American Journal of Cardiology·J E BurchenalJ A Bittl
Sep 12, 1998·Annals of Internal Medicine·P J SharisJ Loscalzo
Apr 6, 1999·The American Journal of Cardiology·S H WilsonP B Berger

❮ Previous
Next ❯

Citations

Dec 6, 2006·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·S M SaidR Prondzinsky
Feb 7, 2013·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Samir M SaidRuediger C Braun-Dullaeus
Dec 23, 2008·Journal of Thrombosis and Thrombolysis·Tobias HeerUNKNOWN Acute Coronary Syndromes (ACOS) Registry Investigators
Jun 18, 2009·Internal and Emergency Medicine·Matteo Nicola Dario Di MinnoGiovanni Di Minno
Sep 8, 2006·The New England Journal of Medicine·Gilles MontalescotUNKNOWN STEEPLE Investigators
Nov 17, 2009·The New England Journal of Medicine·Robert A HarringtonDeepak L Bhatt
Oct 24, 2008·The New England Journal of Medicine·Cynthia A JackeviciusLouise Pilote
Mar 1, 2006·Journal of Clinical Pathology·A K Mitra, D K Agrawal
Nov 16, 2005·Cardiology·Yuval KonstantinoDavid Hasdai
Sep 15, 2005·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Brendan Duffy, Deepak L Bhatt
Nov 7, 2006·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Michael J Lipinski, George W Vetrovec
Jun 8, 2011·EuroIntervention : Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·Pascal VranckxPatrick Serruys
May 1, 2006·Future Cardiology·Udaya S TantryPaul A Gurbel
Sep 1, 2005·Future Cardiology·Daniel C Bezerra, Julien Bogousslavky
Oct 28, 2005·Cardiovascular and Interventional Radiology·T RandJ Lammer
Jul 9, 2008·Journal of Clinical Gastroenterology·Kassem BaradaPeter H Green
Dec 24, 2005·Expert Opinion on Pharmacotherapy·Simone C BukowMichael G Hennerici
Apr 12, 2007·Expert Opinion on Pharmacotherapy·Andrew J Lucking, David E Newby
Jul 25, 2006·Expert Opinion on Investigational Drugs·Dagmar Kubitza, Sylvia Haas
Jun 10, 2011·The Canadian Journal of Cardiology·Alan D BellUNKNOWN Canadian Cardiovascular Society
Nov 18, 2008·European Journal of Internal Medicine·Massimo Franchini, Pier Mannuccio Mannucci
Jul 27, 2007·Best Practice & Research. Clinical Anaesthesiology·Pierre-Guy ChassotDonat R Spahn
May 3, 2005·Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions·John A Bittl
Sep 15, 2009·Seminars in Dialysis·Arif Asif, Alexander S Yevzlin
Apr 11, 2009·Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions·Marco De CarloA Sonia Petronio
Aug 1, 2007·Journal of Thrombosis and Haemostasis : JTH·J W Eikelboom, J Hirsh

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.